Micro-Cap below Rs 100: High ROE and sales growth company is offering a 33 per cent discount on rights issue

They've announced a record date for the purpose of determining the equity shareholder’s entitled to receive the Rights Entitlement in the Right Issues

Syschem (India) Limited (SIL) isn't just another pharmaceutical company; it's a powerhouse of innovation and commitment. With a team of highly dedicated techno-commercial experts at the helm, SIL has carved a niche for itself in the dynamic world of bulk drug manufacturing and contract manufacturing.

What sets SIL apart is its unwavering global footprint. From the vibrant streets of India to the far-reaching corners of Latin America, the mystical lands of Africa, the bustling markets of Thailand, and even the ancient wonders of Egypt and Sri Lanka, SIL's products have traveled far and wide. They've also conquered the hearts of healthcare providers in Germany, Bangladesh, and the sprawling Middle East and North Africa (MENA) region.

Now, let's delve into the real stars of the show – SIL's key products. These aren't just your run-of-the-mill antibiotics. They're the lifesavers, the defenders against the invisible armies of bacteria. Amoxicillin, Ampicillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Cephalexin, Cefaclor, and Cefadroxil; each of these compounds represents a battle-hardened soldier in the war against bacterial infections.

But that's not all. SIL's clientele includes big names like Himalaya, a testimony to the trust they've garnered in the industry. 

Imagine this: It's a Monday morning, and the stock markets are playing their usual tunes of uncertainty. But amidst the chaos, SIL's stock is dancing to its rhythm, surging by a remarkable 3.5 per cent. It's currently trading at Rs 59.50, making it a captivating micro-cap stock with a market cap of Rs 189 crore. While others may falter, SIL stands tall. The company has delivered good profit growth of 59.3 per cent CAGR over last 5 years. Company has a ROE of 31.8 per cent.

And now, here's the plot twist. SIL isn't just a company with impressive growth; it's also generous. They've announced a record date for the purpose of determining the equity shareholder’s entitled to receive the Rights Entitlement in the Right Issues. On the fateful Friday, September 29, 2023, equity shareholders will gather to witness history. For every 4 equity shares they hold, SIL is offering 1 equity share at Rs 40 per share. It's a gesture that's not just generous but also strategic.

What makes this announcement truly electrifying is the price at which these new shares will be offered. It's a jaw-dropping discount of nearly 33 per cent from the current market price, at just Rs 40 per share. SIL isn't just giving, it's practically handing out golden tickets to its shareholders.

Disclaimer: The article is for informational purposes only and not investment advice.